Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU
NCT ID: NCT05741424
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2023-03-08
2024-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Innovative technologies have emerged to shorten the turnaround time of blood culture samples by obtaining susceptibility testing of the incriminated pathogen at an early stage, and therefore to rapidly adjust the antibiotic therapy of patients with Gram-negative Bacilli bacteremia.
The study investigators hypothesize that the implementation of the innovative BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® solutions for the analysis of blood culture samples will increase the proportion of patients with Gram-negative Bacilli bacteremia who receive appropriate and optimized antibiotic therapy 24 hours after blood culture collection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
NCT01042353
Coated Devices to Decrease Infection in the Intensive Care Unit
NCT03868241
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
NCT07052604
Impact of Direct Antimicrobial Susceptibility Testing on Respiratory Sample of Intensive Care Patient With Suspected VAP
NCT02897466
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
NCT03752476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
After innovative diagnostic technologies
Innovative diagnostic technologies
Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
Reference diagnostic technique
Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Innovative diagnostic technologies
Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
Reference diagnostic technique
Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient admitted to the ICU with at least one positive blood culture for Gram-negative bacteremia
For the 'after' section of the study only:
* Patient must have given their free and informed consent or included by emergency procedure
* Patient signed the consent form or included by emergency procedure
Exclusion Criteria
* Consent refusal
* Patient with a polymicrobial blood culture
* Patient with a second episode of bacteremia
* Moribund patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioMérieux
INDUSTRY
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alix Pantel
Role: PRINCIPAL_INVESTIGATOR
CHU de Nimes
Claire Roger
Role: PRINCIPAL_INVESTIGATOR
CHU de Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nîmes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oudiane L, Benyahia M, Salipante F, Dubois A, Muller L, Lavigne JP, Pantel A, Roger C. Clinical impact of the BCID2 and rapid AST VITEK(R) REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study. J Antimicrob Chemother. 2025 Oct 3;80(10):2665-2675. doi: 10.1093/jac/dkaf271.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIVI/2022/AP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.